# Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

> **NCT03476239** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 121 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Dexamthasone

## Key facts

- **NCT ID:** NCT03476239
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-18
- **Primary completion:** 2019-08-21
- **Final completion:** 2021-04-08
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03476239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03476239, "Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03476239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*